Schneeberger S, Ninkovic M, Gabl M, Ninkovic M, Hussl H, Rieger M, Loescher W, Zelger B, Brandacher G, Bonatti H, Hautz T, Boesmueller C, Piza-Katzer H, Margreiter R
Department of General and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria.
Am J Transplant. 2007 Jul;7(7):1753-62. doi: 10.1111/j.1600-6143.2007.01837.x. Epub 2007 May 19.
We here report on the surgical procedure, postoperative course and functional results at 3 years following the first bilateral forearm transplantation. A 41-year-old male underwent bilateral forearm transplantation on February 17, 2003. After ATG induction therapy, tacrolimus, prednisone and MMF were given for maintenance immunosuppression. At 16 months, MMF was switched to everolimus. Hand function, histology, immunohistochemistry, radiomorphology, motor and nerve conduction and somatosensory-evoked potentials were investigated at frequent intervals. A total of six rejection episodes required treatment with either steroids, basiliximab, ATG, alemtuzumab or tacrolimus dose augmentation. At 3 years, the patient is free of clinical signs of rejection despite a persisting minimal perivascular lymphocytic dermal infiltrate. No signs of myointimal proliferation in graft vessels were seen. Motor function continuously improved, resulting in satisfactory hand function. Intrinsic hand muscle function was first observed at 16 months and continues to improve. Although discrimination of hot and cold recovered, overall sensitivity remains poor. The patient is satisfied with the outcome. Bilateral forearm transplantation represents a novel therapeutic option after loss of forearms.
我们在此报告首例双侧前臂移植术后3年的手术过程、术后病程及功能结果。一名41岁男性于2003年2月17日接受了双侧前臂移植手术。在接受抗胸腺细胞球蛋白诱导治疗后,给予他克莫司、泼尼松和霉酚酸酯进行维持免疫抑制治疗。16个月时,将霉酚酸酯换为依维莫司。定期对手功能、组织学、免疫组织化学、放射形态学、运动及神经传导和体感诱发电位进行研究。共有6次排斥反应发作,需使用类固醇、巴利昔单抗、抗胸腺细胞球蛋白、阿仑单抗或增加他克莫司剂量进行治疗。3年后,尽管仍存在轻微的血管周围淋巴细胞皮肤浸润,但患者无排斥反应的临床体征。在移植血管中未见肌内膜增殖迹象。运动功能持续改善,手部功能令人满意。内在手部肌肉功能在16个月时首次出现,并持续改善。虽然冷热辨别能力有所恢复,但总体感觉仍较差。患者对结果满意。双侧前臂移植是前臂缺失后的一种新的治疗选择。